Home / Investor Relations / CEO Commentaries

CEO Commentaries

No Blood, No Tumor

Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.
Read More

Big Data, Fewer Cells

Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
Read More

3D Culture

Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.
Read More

Big Pharma, Big Data

Imaged-based time-lapse cytometers, as our HoloMonitor, creates huge amounts of information on how cells interact and multiply over long time periods. Com­bi­ned with Big Data technology, such novel instru­menta­tion will provide cell bio­lo­gists and the pharmaceutical industry with a game changing new tool to better understand complex cellular interactions and through this hopefully cure cancer.
Read More

Label-free High Content Screening

The current form of high-content screening is based on conventional microscopy. The core technology of HoloMonitor, holographic time-lapse microscopy, creates 3D-movies of unstained living cells that can be computer-processed without requiring the use of toxic labels. This new ability opens the door to more realistic high-content screening of living cells and their behavior over time.
Read More

Immunothearpy

The progress by Northeastern University and other customers have shown that HoloMonitor technology has the potential to be the non-destructive tool that makes large scale immunotherapies successful and affordable to all patients.
Read More